Risk factors associated with metabolic syndrome and cardiovascular disease among women with polycystic ovary syndrome in Tabuk, Saudi Arabia

Authors

  • Amani Ali Shaman M.D., Assistant Professor in Obstetrics and Gynecology, Faculty of Medicine, University of Tabuk, Tabuk, Kingdom of Saudi Arabia

Keywords:

olycystic ovary syndrome, Metabolic syndrome, Cardiovascular disease

Abstract

Background: Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder at a reproductive age. It is associated with a high risk of metabolic syndrome (MS) and cardiovascular diseases (CVD). 

Objective: To measure the prevalence of MS in women with PCOS and to assess the global cardiovascular risk (CVR) among them.

Methods: This cross-sectional study was conducted at King Khalid Hospital, Tabuk, Saudi Arabia during the period from February through December 2014. A total of 404 infertile women were randomly selected, and checked for diagnosing PCOS, MS and estimated CVD probability. Data were analyzed by IBM-SPSS version 22, using independent-samples t-test, Chi-square, and conditional logistic regression. A p-value of <0.05 was considered significant.

Results: MS was diagnosed in 58% and 32% of women with and without PCOS respectively (p<0.00). Results showed a statistically significant association between the two syndromes. Patients with the two syndromes showed high averages of clinical and biochemical values (p<0.00), high rate of predicted CVR, a high percentage of clustering of MS factors, and that weight-waist circumference - HDL are predictive for the occurrence of MS.

Conclusion: PCOS is associated with the risk of development of MS, and CVD. Screening for early detection of PCOS and MS and the application of cohort studies are recommended to better explore the role of PCOS in the development of CVD and to assess the significance of interventions.

References

Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007; 370(9588): 685- 97. doi: 10.1016/S0140-6736(07)61345-2.

March WA, Moore VM, Wilson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic

ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;

(2): 544-51. doi: 10.1093/humrep/dep399. PMID: 19910321.

Marcondes JAM, Barcellos CRG, Rocha MP. Dificuldades e armadilhas no diagnostico da syndrome dos

ovlriospolicysticos. Arq Bras Endocrinol Metab. 2011; 55(1): 6-15. doi: 10.1590/S0004- 27302011000100002.

Al-Ruhaily AD, Malabu UH, Sulimani RA. Hirsutism in Saudi females of reproductive age: a hospital- based study. Ann Saudi Med. 2008; 28(1): 28-32. doi: 10.4103/0256-4947.51762. PMID: 18299651.

Iftikhar S, Collazo-Clavell ML, Roger VL, St Sauver J, Brown RD Jr, Cha S, et al. Risk of cardiovascular

events in patients with polycystic ovary syndrome. Neth J Med. 2012; 70(2): 74-80. PMID: 22418753,

PMCID: PMC3582228.

Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose intolerance, type 2 diabetes and metabolic

syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update.

; 16(4): 347-63. doi: 10.1093/humupd/dmq001. PMID: 20159883.

Malik S, Wong ND. Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis.

Expert Rev Cardiovasc Ther. 2009; 7(3): 273-80. doi: 10.1586/14779072.7.3.273. PMID: 19296765.

Rouzi A, Ardawi M. Prevalence of the metabolic syndrome in Saudi women ad its components with

polycystic ovary syndrome. 8th European Congress on Menopause (EMAS). Maturitas. 2009;

(Supplement 1): S1–136.

Cobin RH. Cardiovascular and metabolic risks associated with PCOS. Intern Emerg Med. 2013; 8 (Suppl

: S61-4.

Scicchitano P, Dentamaro I, Carbonara R, Bulzis G, Dachille A, Caputo P, et al. Cardiovascular Risk in

Women with PCOS. Int J EndocrinolMetab. 2012; 10(4): 611-8. doi: 10.5812/ijem.4020. PMID: 23843832,

PMCID: PMC3693634.

Oliveira Rdo S, Redorat RG, Ziehe GH, Mansur VA, Conceição FL. Arterial hypertension and metabolic

profile in patients with polycystic ovary syndrome. Rev Bras Ginecol Obstet. 2013; 35(1):21-6. doi:

1590/S0100-72032013000100005. PMID: 23338549.

Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic

ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod.

; 28: 777-84. doi: 10.1093/humrep/des463. PMID: 23315061.

Wong ND, Pio JR, Franklin SS, L’Italien GJ, Kamath TV, Williams GR. Preventing coronary events by

optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol. 2003;

: 1421-26. doi: 10.1016/S0002-9149(03)00392-8.

Cussons AJ, Stuckey BGA, Watts GF. Cardiovascular disease in the polycystic ovary syndrome. new

insights and perspectives. Atherosclerosis. 2006; 185: 227-39. doi: 10.1016/j.atherosclerosis.2005.10.007.

PMID: 16313910.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on

diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril. 2004;

(1): 19-25. doi: 10.1016/j.fertnstert.2003.10.004.

Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition: a consensus statement

from the International Diabetes Federation. Diabet Med. 2006; 23: 469–80. doi: 10.1111/j.1464- 5491.2006.01858.x. PMID: 16681555.

Risk Scoring Systems. 2013. Available from: http://www.framinghamheartstudy.org/.

Onaka L. Lipids. In Clinical Chemistry Concepts and Applications. London: W.B. Saunders; 1993.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein

cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502. PMID:

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and

management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood

Institute Scientific Statement. Circulation. 2005; 112: 2735–52. doi:

1161/CIRCULATIONAHA.105.169404. PMID: 16157765.

Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,

Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report.

Circulation. 2002; 106: 3143–421. PMID: 12485966.

Panidis D, Farmakiotis D, Rousso D, Katsikis I, Kourtis A, Diamanti-Kandarakis E. Serum

luteinizinghormone levels are markedly increased and significantly correlated with D4-androstenedione

levels in lean women with polycystic ovary syndrome. Fertil Steril. 2005; 84: 538-40. doi:

1016/j.fertnstert.2005.02.017. PMID: 16084906.

Spritzer PM. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.

Arq Bras Endocrinol Metabol. 2014; 58(2): 182-7. doi: 10.1590/0004-2730000003051. PMID: 24830595.

de Vries L, Karasik A, Landau Z, Phillip M, Kiviti S, Goldberg-Stern H. Endocrine effects of valproate in

adolescent girls with epilepsy. Epilepsia. 2007; 48: 470-7. doi: 10.1111/j.1528-1167.2006.00953.x. PMID:

Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among

premenopausal women with type 2 diabetes. Diabetes Care. 2001; 24: 1050-2. doi:

2337/diacare.24.6.1050. PMID: 11375369.

Moini A, Javanmard F, Eslami B, Aletaha N. Prevalence of metabolic syndrome in polycystic ovarian

syndrome women in a hospital of Tehran. Iran J Reprod Med. 2012; 10(2): 127-30.

Paul S, Smith L. The metabolic syndrome in women: a growing problem for cardiac risk. J Cardiovasc

Nurs. 2005; 20(6): 427–32. doi: 10.1097/00005082-200511000-00011.

Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review

and meta-analysis. Fertil Steril. 2011; 95: 1073-9.

Luo X, Xu L. Association of fat distribution with metabolic syndrome in patients with polycystic ovary

syndrome. Nan Fang Yi Ke Da Xue Xue Bao. 2012; 32: 1325‑7. PMID: 22985575.

Hudecova M, Jan H, Christian B, PoromaaInger S. Longterm Reproductive and Metabolic Consequences of

PCOS. Curr Diabetes Rev. 2012; 8: 444‑51. doi: 10.2174/157339912803529913. PMID: 22934549.

Al Mulhim AA, Abul Heija AA, Al Talib AA, Al Turki HA, Gasim TG. Hormonal, Metabolic and Clinical

Profile of Saudi Women with Polycystic Ovary Syndrome. Saudi Journal of Medicine & Medical Sciences.

; 1(1): 30-34. doi: 10.4103/1658-631X.112920.

Zachurzok Buczynska A, Szydlowski L, Gawlik A, Wilk K, Malecka‑Tendera E. Blood pressure regulation

and resting heart rate abnormalities in adolescent girls with polycystic ovary syndrome. Fertil Steril. 2011;

: 1519-23. doi: 10.1016/j.fertnstert.2011.09.043. PMID: 22032814.

Azevedo MF, Costa EC, Oliveira AI, Silva IB, Marinho JC, Rodrigues JA, et al. Elevated blood pressure in

women with polycystic ovary syndrome: Prevalence and associated risk factors. Rev Bras Gynecol Obstet

; 33: 31-6. PMID: 21625791.

Martins WdP, Soares GM, Vieira CS, Reis RMd, SáMFSd, Ferriani RA. Radiographic Assessment of

Maxillary Sinus Lateral Wall Thickness in Edentulous Posterior Maxilla. Revista Brasileira de Ginecologia

e Obstetrícia. 2009; 31:111-6. PMID: 19547885.

Li R, Yu G, Yang D, Li S, Lu S, Wu X, et al. Prevalence and predictors of metabolic abnormalities in

Chinese women with PCOS: a cross- sectional study. BMC Endocr Disord. 2014; 14: 76. doi:

1186/1472-6823-14-76. PMID: 25223276, PMCID: PMC4171713.

Cavanaugh-Hussey MW, Berry JD, Lloyd-Jones DM. Who exceeds ATP-III risk thresholds? Systematic

examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool. Prev

Med. 2008; 47: 619–23. doi: 10.1016/j.ypmed.2008.07.012. PMID: 18718484, PMCID: PMC2630457.

Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham Heart Study general

cardiovascular risk profile. Circulation. 2009; 120: 384–90. doi:

1161/CIRCULATIONAHA.108.835470. PMID: 19620502.

Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime

risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006; 113: 791–8. doi:

1161/CIRCULATIONAHA.105.548206. PMID: 16461820.

Di Domenico K, Wiltgen D, Nickel FJ, Magalhães JA, Moraes RS, Spritzer PM. Cardiac autonomic

modulation in polycystic ovary syndrome: does the phenotype matter? Fertil Steril. 2013; 99(1): 286-92.

doi: 10.1016/j.fertnstert.2012.08.049. PMID: 23025880.

Published

2022-02-12